This was the stock's second consecutive day of losses.

Biogen (BIIB) announced the appointment of Adam Feire, Ph.D., as Head of Business Development and External Innovation. Feire reports to Adam ...

Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first ...

The stock's fall snapped a two-day winning streak.

Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

Piper Sandler downgraded Biogen (NASDAQ:BIIB) to neutral from overweight on Thursday, citing, among other things, the company ...

Truist analyst Srikripa Devarakonda lowered the firm’s price target on Biogen (BIIB) to $220 from $302 and keeps a Buy rating on the shares as ...

The Biogen Inc. story of the last 10 years has been one of periods of excitement, followed by significant disappointments.

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

In order from steepest decline to narrowest, the five unloved were Intel ( INTC 1.68%), MongoDB ( MDB 0.72%), Biogen ( BIIB 1 ...

Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new ...